High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.

[1]  P. Marcellin,et al.  Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C , 2006, Journal of viral hepatitis.

[2]  H. Wedemeyer,et al.  Treating viral hepatitis C: efficacy, side effects, and complications , 2006, Gut.

[3]  L. Messerini,et al.  Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. , 2006, Gastroenterology.

[4]  P. Adeleine,et al.  Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). , 2006, Journal of hepatology.

[5]  M. Manns,et al.  Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. , 2006, Journal of hepatology.

[6]  X. Forns,et al.  Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C , 2006, Hepatology.

[7]  T. Asselah,et al.  STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? , 2005, Gut.

[8]  M. Richardson,et al.  Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 , 2005, Gut.

[9]  E. Bini,et al.  A Randomized Trial of Pegylated Interferon α-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C , 2005, The American Journal of Gastroenterology.

[10]  D. Dhumeaux,et al.  Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. , 2005, Journal of hepatology.

[11]  T. Ashikaga,et al.  Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. , 2005, Journal of hepatology.

[12]  P. Marcellin,et al.  Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis , 2005, Journal of viral hepatitis.

[13]  B. Neuschwander‐Tetri,et al.  Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  R. Andrade,et al.  Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.

[15]  I. Siddique,et al.  Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin. , 2004, Antiviral therapy.

[16]  William M. Lee,et al.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.

[17]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[18]  S. Zeuzem.  Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? , 2004, Annals of Internal Medicine.

[19]  J. McHutchison,et al.  The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. , 2004, Journal of hepatology.

[20]  T. Berg,et al.  Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C , 2003 .

[21]  M. Manns,et al.  Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.

[22]  M. Shiffman.  Retreatment of patients with chronic hepatitis C , 2002, Hepatology.

[23]  K. Reddy,et al.  Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). , 2002, Journal of hepatology.

[24]  T. Berg,et al.  Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy , 2002, Hepatology.

[25]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[26]  E. Schiff,et al.  A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C , 2001, Hepatology.

[27]  G. Tomlinson,et al.  High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C , 2003, Hepatology.

[28]  B. Bacon,et al.  Combination of interferon and ribavirin in chronic hepatitis C: Re‐treatment of nonresponders to interferon , 2001, Hepatology.

[29]  S. Goodman,et al.  Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. , 2001, JAMA.

[30]  J. Wong,et al.  Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta‐analysis of controlled and uncontrolled trials , 2001, Hepatology.

[31]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[32]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[33]  J. Albrecht,et al.  The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. , 2000, Gastroenterology.

[34]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[35]  William M. Lee,et al.  Early Hepatitis C virus–RNA responses predict interferon treatment outcomes in chronic hepatitis C , 1998, Hepatology.

[36]  P. Marcellin,et al.  Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. , 1998, Clinical biochemistry.

[37]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[38]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[39]  G. Giannelli,et al.  Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. , 2005, The new microbiologica.

[40]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .